MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor

To identify molecular determinants of histone deacetylase inhibitor (HDI) resistance, we selected HuT78 cutaneous T-cell lymphoma (CTCL) cells with romidepsin in the presence of P-glycoprotein inhibitors to prevent transporter upregulation. Resistant sublines were 250- to 385-fold resistant to romid...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Chakraborty, Arup R., Robey, Robert W., Luchenko, Victoria L., Zhan, Zhirong, Piekarz, Richard L., Gillet, Jean-Pierre, Kossenkov, Andrew V., Wilkerson, Julia, Showe, Louise C., Gottesman, Michael M., Collie, Nathan L., Bates, Susan E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2013
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3656450/
https://ncbi.nlm.nih.gov/pubmed/23532732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2012-08-449140
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados